Aermony RespiClick™ (fluticasone propionate
inhalation powder), available in three dose options
- Asthma is a chronic, lifelong condition without a cure that
can cause life-threatening symptoms and affects 3.8 million
Canadians.1–3
- Although inhaled medication is the cornerstone of therapy,
incorrect inhaler technique is common—indicating that device
selection is important and can affect
outcomes.4
MONTRÉAL, Oct. 5, 2020 /CNW/
- Teva Canada, a subsidiary of Teva Pharmaceutical Industries
Ltd., today announced product availability of Aermony RespiClick™,
indicated for the maintenance treatment of steroid-responsive
bronchial asthma as prophylactic therapy in patients 12 years of
age and older5 and offered in a simple-to-use
inhaler.
Aermony RespiClick™ (fluticasone propionate inhalation powder)
is packaged in an innovative device with features designed to
simplify the administration of inhaled therapy and reduce patient
error and confusion. One key feature is the innovative cap that
integrates the opening and priming steps—thereby minimizing
patients' coordination errors. A "click" sound confirms that the
dose is ready, which helps support patient confidence in their dose
and device.5
"Devices play a central role in the success of asthma therapy
since the evidence clearly demonstrates an important association
between inhaler errors and suboptimal asthma control.1
It stands to reason that a device that is simple to use may also
minimize errors that may lead to poor asthma control," said Dr.
Anthony D'Urzo, a practising family physician and researcher at the
University of Toronto. "Aermony
RespiClick™ has desirable 'user-friendly' features that make it a
welcome addition for patients who require maintenance therapy with
a medication like fluticasone propionate."
"We're pleased that Aermony RespiClick™ is now available in
Canada. With this innovative
method of delivery of medication, respirologists and asthma
patients will experience the simplified administration features the
RespiClick™ device has to offer," said Christine Poulin, general manager of
Teva Canada. "Aermony RespiClick™ is
a meaningful expansion of our offerings in respirology, which
currently include both proprietary and generic products."
Fluticasone propionate, the active ingredient in Aermony
RespiClick™, has been extensively studied in clinical trials and
has been available in the Canadian market for 27 years, since
1993.2 Aermony RespiClick™ will enter the market
offering a price advantage compared to the branded fluticasone
propionate inhalation powder and will come in three dose
options:
- 55 mcg per actuation
- 113 mcg per actuation
- 232 mcg per actuation
Patients using Aermony RespiClick™ take one inhalation twice
daily at the same time every day, approximately 12 hours
apart.5
About bronchial asthma
Asthma is a chronic inflammatory disease of the airway that
causes trouble breathing.3 It is a lifelong condition
without a cure that affects 3.8 million people in Canada.3,4,6 Six out of ten people
do not have control of their disease.6 The cause of
asthma remains unknown, but it is not contagious and appears to be
caused by both hereditary and environmental factors.6 An
attack is often triggered by something in the environment, such as
dust mites, animals, pollens, and viral infections, but the
triggers are individual to each patient.7 An attack can
happen suddenly and be life threatening.8 Inhalers are
the cornerstone of treatment, but, despite the potential benefits
of inhaler therapy, evidence suggests that many patients do not use
their inhalers correctly.9 Therefore, device selection
may play an important role in an individual patient's success on
therapy.
About Aermony RespiClickTM
Aermony RespiClick™ is indicated for the maintenance treatment
of steroid-responsive bronchial asthma as prophylactic therapy in
patients 12 years of age and older. Aermony RespiClick™ is
available in three dose options: 55 mcg, 113 mcg, and 232 mcg per
actuation. It is dosed as one inhalation twice daily at the same
time every day, approximately 12 hours apart.
Helping improve the lives of Canadians
At Teva, we care deeply about the well-being of the patients,
caregivers, and communities that rely on us. We serve 200 million
people every day, with a promise to help them take better control
of their health. From our role as a global leader in generic and
brand-name medicines to the innovative solutions we create for our
healthcare partners, we offer a unique perspective on health—here
in Canada and around the
world.
About Teva Canada
Teva Canada, headquartered in
Toronto, has provided affordable
healthcare solutions to Canadians for over 50 years, building their
trust one prescription at a time with now more than
217,00010 prescriptions filled each day with our
products. Originally Novopharm Limited, Teva Canada specializes in the development,
production, and marketing of high-quality generic prescription
pharmaceuticals and, through our branded division, focuses on a
diverse line of innovative products in a variety of therapeutic
areas. Teva Canada employs more than
900 professionals, had sales of nearly $1.3
billion10 in 2019, and markets more than 385
products in 1,000 SKUs10 in Canada. We are a proud subsidiary of Teva
Pharmaceutical Industries Ltd. Learn more at
www.tevacanada.com.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people's lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
____________________________________
SKU: stock-keeping
unit
|
|
|
1.
|
Usmani OS, Lavorini
F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a
systematic review of impact on health outcomes. Respir Res.
2018;19:10.
|
2.
|
Health Canada Drug
Product Database. Search for: fluticasone propionate. Available
from: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp.
Last accessed: September 1, 2020.
|
3.
|
Asthma Canada.
Understanding asthma: what is asthma? Available
from: https://asthma.ca/what-is-asthma/. Last accessed:
September 1, 2020.
|
4.
|
Asthma Canada.
Frequently asked questions. Available from:
https://asthma.ca/get-help/understanding-asthma/frequently-asked-questions/.
Last accessed: September 1, 2020.
|
5.
|
Aermony RespiClick™
Product Monograph. Teva Canada. December 14, 2018.
|
6.
|
Asthma Canada. Who
gets asthma? Available from:
https://asthma.ca/get-help/understanding-asthma/. Last accessed:
September 1, 2020.
|
7.
|
Asthma Canada. Common
asthma triggers. Available from:
https://asthma.ca/get-help/asthma-triggers/. Last accessed:
September 1, 2020.
|
8.
|
Asthma Canada. What
is an asthma attack? Available from:
https://asthma.ca/get-help/living-with-asthma/asthma-attacks/. Last
accessed: September 1, 2020.
|
9.
|
Murphy A. How to help
patients optimise their inhaler technique. Pharm J.
2016;297(7891). DOI: 10.1211/PJ.2016.20201442.
|
10.
|
Source: IQVIA CDH
& Compuscript MAT. April 2020.
|
SOURCE Teva Canada